Abcam to Report Interim Results on Monday, March 8, 2021
February 26 2021 - 2:00AM
Abcam plc (AIM: ABC; Nasdaq: ABCM) (“
Abcam” or the
“
Company”), a global leader in the supply of life
science research tools, will report its Interim Results for the
six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00
a.m. EST) on Monday, March 8, 2021.
Following the announcement, the
Company will host a live teleconference and webcast at 2:00 p.m.
GMT (9:00 a.m. EST) that same day (details below).
To access the webcast, please use the
following link: https://edge.media-server.com/mmc/p/zejeosdn
To participate in the call, please
find details below:
Date: |
Monday, March 8, 2021 |
Time: |
0900 EST / 1400 GMT |
Dial-in: |
United Kingdom
|
+44 (0) 800 694 1461(Toll Free) / +44 (0) 844 493 6766 (Local) |
United States |
+1 866 280 1157 (Toll Free) / +1 646 787 1226 (Local) |
All other locations |
+44 (0) 203 009 5709 |
Conference ID: |
7268122 |
The press release and the live audio
webcast will also be available in the investor section of Abcam’s
corporate website at
corporate.abcam.com/investors/reports-presentations/. An archive
will be available after the call at that same address.
For further
information, please contact:
Abcam
James Staveley, VP Investor Relationsjames.staveley@abcam.com + 44
(0) 1223 696 000
Numis -
Nominated Adviser & Joint Corporate BrokerGarry Levin
/ Duncan Monteith / Huw Jeremy+ 44 (0) 20 7260 1000
About Abcam
plcAs an innovator in reagents and tools, Abcam's purpose
is to serve life science researchers globally to achieve their
mission, faster. Providing the research and clinical communities
with tools and scientific support, the Company offers highly
validated antibodies, assays and other research tools to address
important targets in critical biological pathways.
Already a pioneer in
data sharing and ecommerce in the life sciences, Abcam's ambition
is to be the most influential company in life sciences by helping
advance global understanding of biology and causes of disease,
which, in turn, will drive new treatments and improved health.
Abcam's worldwide
customer base of approximately 750,000 life science researchers
uses Abcam's antibodies, reagents, biomarkers and assays. By
actively listening to and collaborating with these researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Founded in 1998 and
headquartered in Cambridge, UK, the Company has served customers in
more than 130 countries. Abcam’s ordinary shares are listed on the
London Stock Exchange (AIM: ABC) and its American Depositary Shares
(ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).
For more information,
please visit www.abcam.com or www.abcamplc.com
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any express or implied statements contained in
this announcement that are not statements of historical fact may be
deemed to be forward-looking statements, including, without
limitation, statements regarding Abcam’s expectation of reporting
Interim Results and holding the related teleconference on March 08,
2021, Abcam's portfolio and ambitions, expected performance for
first half 2021, as well as statements that include the words
“expect,” “intend,” “plan,” “believe,” “project,” “forecast,”
“estimate,” “may,” “should,” “anticipate” and similar statements of
a future or forward-looking nature. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation: a
regional or global health pandemic, including the novel coronavirus
(“COVID-19”), which has adversely affected elements of our
business, could severely affect our business, including due to
impacts on our operations and supply chains; challenges in
implementing our strategies for revenue growth in light of
competitive challenges; developing new products and enhancing
existing products, adapting to significant technological change and
responding to the introduction of new products by competitors to
remain competitive; failing to successfully identify or integrate
acquired businesses or assets into our operations or fully
recognize the anticipated benefits of businesses or assets that we
acquire; if our customers discontinue or spend less on research,
development, production or other scientific endeavours; failing to
successfully use, access and maintain information systems and
implement new systems to handle our changing needs; cyber security
risks and any failure to maintain the confidentiality, integrity
and availability of our computer hardware, software and internet
applications and related tools and functions; failing to
successfully manage our current and potential future growth; any
significant interruptions in our operations; if our products fail
to satisfy applicable quality criteria, specifications and
performance standards; failing to maintain our brand and
reputation; our dependence upon management and highly skilled
employees and our ability to attract and retain these highly
skilled employees; and the important factors discussed under the
caption “Risk Factors” in Abcam's prospectus pursuant to Rule
424(b) filed with the U.S. Securities and Exchange Commission
(“SEC”) on 22 October 2020, which is on file with the SEC and is
available on the SEC website at www.sec.gov, as such factors may be
updated from time to time in Abcam's other filings with the SEC.
Any forward-looking statements contained in this announcement speak
only as of the date hereof and accordingly undue reliance should
not be placed on such statements. Abcam disclaims any obligation or
undertaking to update or revise any forward-looking statements
contained in this announcement, whether as a result of new
information, future events or otherwise, other than to the extent
required by applicable law.
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abcam (NASDAQ:ABCM)
Historical Stock Chart
From Sep 2023 to Sep 2024